Colorectal Cancer Clinical Trials

Showing 61-80 of 2,972 trials

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

NCT03803553

This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab

Metastatic Colon CancerStage III Colon Cancer

Massachusetts General Hospital400 participantsStarted Apr 2020

Boston, Massachusetts, United States • New York, New York, United States • New York, New York, United States

COMPLETEDPhase 2

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

NCT05004350

Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic colorectal cancer (mCRC), who have received prior systemic therapy.

BRAF V600EMetastatic Colorectal Cancer

Pierre Fabre Medicament107 participantsStarted Sep 2021

Beijing, Beijing Municipality, China • Beijing, Beijing Municipality, China • Fuzhou, Fujian, China +31 more locations

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Related Searches

Early-Onset Colorectal Cancer Patients Too Young for Screening

FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients

Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer

Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer

Remote Monitoring and Symptom Management Digital Application

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Physical Activity in Relation to Surgical Procedures

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors

Effectiveness of Using Mobile Health Technology in Colorectal Cancer Screening Uptake

Comparison of Expression of Carcinogenesis-related Molecular Markers in the Patients With Colon Cancer and Polyp

Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

Acute Colon Resection Versus Bridge to Colon Surgery With Stent or Stoma

ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma

AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)